Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 71.00
Bid: 67.00
Ask: 75.00
Change: 0.00 (0.00%)
Spread: 8.00 (11.94%)
Open: 71.00
High: 71.00
Low: 71.00
Prev. Close: 71.00
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Feedback Joins NHS AI Procurement Framework

29 Sep 2021 07:00

RNS Number : 2755N
Feedback PLC
29 September 2021
 

 

Feedback plc

 

RNS REACH

 

Feedback appointed to national NHS AI procurement framework

 

· The national framework addresses the Provision of Artificial Intelligence (A.I), Imaging and Radiotherapy Equipment, Associated Products and Diagnostic Imaging to public and private sector organisations

· Bleepa has been awarded onto the framework as a product which can facilitate the deployment of AI imaging tools into frontline clinical settings through mobile devices, enabling on-the-go access to AI

· The framework's estimated overall value of up to £360m enables any NHS body a route to procure the Bleepa AI solution for the purpose of developing, evaluating or clinically delivering AI imaging tools

 

London, 29 September 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that it has been awarded a place on a national procurement framework: The Provision Artificial Intelligence (A.I), Imaging and Radiotherapy Equipment, Associated Products and Diagnostic Imaging.

 

The Company has developed an AI module for the Bleepa communication platform that enables third party AI tools to be deployed within the app by frontline clinical users in order to assist with the diagnostic interpretation of medical imaging studies such as X-rays, CT scans and MRIs. The AI module has already been configured to deploy the AI tools of our commercial partners Qure.ai and Axial 3D.

 

The Bleepa AI module will allow NHS Bleepa customers to engage with AI tools of their choosing, knowing that they have a secure route of deployment right into the hands of their clinicians. Bleepa's availability as a mobile platform allows these AI tools to be deployed in any connected setting realising the full benefits of AI driven point-of-care diagnostics in more places and in a way that can't be recognised through traditional PACS based deployment, that is largely confined to desktop PCs within hospitals.

 

Enabling on-the-go access to the latest AI diagnostic support tools is the next evolution in the Company's mission to enable clinicians to make better decisions faster from any location. The framework will allow NHS organisations to buy the Bleepa AI solution as a platform for AI tool deployment, allowing them to meaningfully engage with any number of AI tools knowing that there is one common route for deployment into their clinical setting. The Company will additionally charge the AI companies a deployment fee through the platform.

 

The framework is run by Shared Business Services (SBS) on behalf of NHS organisations and enables NHS customers to directly procure equipment related to AI imaging, including Bleepa's AI module. The framework has an estimated overall value of up to £360m which lasts until 02/05/2025 and will be a key resource to enable the NHS to engage with AI technology. Details of the framework can be found at:

https://uk.eu-supply.com/ctm/Supplier/PublicTenders/ViewNotice/27445 

 

SBS describe the framework: "This is a framework agreement for the supply of Artificial Intelligence software and platforms and also for the supply of Medical Imaging and Radiotherapy equipment, associated products and Diagnostic Imaging equipment. The framework aims to provide a simple, effective, efficient and compliant route to market for the purchase/supply of a broad range of medical imaging and radiology products and services, including related artificial intelligence solutions. This will be for use by both NHS Customers (and other public & private sector organisations) through means of either direct call-off or further competition if required."

 

Dr Tom Oakley, CEO of Feedback, said: "This national framework is recognition of the increasing interest in AI technology across the NHS and will enable NHS customers to directly procure the Bleepa AI module as a vehicle for delivering the ever-growing array of AI imaging tools available. Clinicians do not want multiple apps on their devices and there is a clear role for a single platform that facilitates the deployment of multiple AI tools. As a mobile first solution, that additionally facilitates patient pathways and clinical case discussion, Bleepa is the perfect deployment platform for AI tools, we can put the latest AI technology literally into the hands of clinicians, through their own devices, in any internet connected location, allowing truly on-the-go access to the best available diagnostic support tools and point-of-care deployment of AI technology in even more care settings."

 

 

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0)1954 718072

IR@fbk.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Emma Earl/Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.

 

About NHS Shared Business Services

 

Established in 2005 by the Department of Health and Social Care (DHSC) in a partnership with digital experts Sopra Steria, its services are aimed at increasing efficiency and quality, saving time and money, and supporting patient care. The DHSC is transforming its current multiple delivery pathways into one intelligent, interconnected ecosystem that meets the ever-changing needs of the NHS in the digital world. Offering a seamless experience with a single sign-on, its modular solutions are aimed at enabling NHS organisations and suppliers to access the services they need, when they need them including access to suppliers or tendering for a multi-million pound project.

 

https://www.sbs.nhs.uk

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEVLFLFKLZBBZ
Date   Source Headline
30th Jun 20172:21 pmRNSHolding(s) in Company
30th Jun 201712:41 pmRNSIssue of Equity
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.